```html

Zollinger‑Ellison Associated Gastrin‑Producing Neuroendocrine Tumor

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by gastrin‑producing neuroendocrine tumors (NETs) that arise primarily in the pancreas or duodenum. These tumors, called gastrinomas, secrete excessive amounts of the hormone gastrin, leading to massive gastric acid production. The resulting hyperacidity causes severe peptic ulcer disease, diarrhea, and malabsorption.

Who it affects: ZES can develop at any age but most cases are diagnosed between the ages of 30 and 60. Men and women are affected equally. Approximately 25 % of patients have a hereditary predisposition (multiple endocrine neoplasia type 1, MEN‑1), while the remainder have sporadic tumors.

Prevalence: Gastrinomas are the second‑most common functional pancreatic NET, with an estimated incidence of 0.5–2 cases per million people per year (NIH, 2022). Because many patients develop ulcer disease before the tumor is identified, the true prevalence may be slightly higher.

Symptoms

The clinical picture of ZES results from two overlapping processes: acid‑related damage to the gastrointestinal (GI) tract and mass‑related effects of the tumor.

Acid‑related symptoms

• Refractory peptic ulcer disease – ulcers that persist despite standard proton‑pump inhibitor (PPI) therapy, often multiple and located beyond the duodenum (jejunum, ileum).
• Epigastric or upper abdominal pain – worsens after meals and may be described as burning.
• Chronic diarrhea – occurs in up to 80 % of patients; can be watery, sometimes fatty (steatorrhea) due to acid‑induced pancreatic enzyme inactivation.
• Nausea & vomiting – especially after large meals.
• Gastroesophageal reflux disease (GERD) – heartburn and acid regurgitation.
• Weight loss – secondary to malabsorption and chronic diarrhea.

Mass‑related symptoms

• Abdominal fullness or bloating – a palpable mass may be present if the tumor is large.
• Early satiety – feeling full after a small amount of food.
• Back or flank pain – can indicate deep retroperitoneal spread.
• Jaundice – if the tumor compresses the bile duct.
• Metastatic signs – liver lesions may cause right‑upper‑quadrant pain or hepatomegaly.

Causes and Risk Factors

Primary cause

ZES is caused by a gastrinoma, a type of neuroendocrine tumor that originates from enterochromaffin‑like cells. These cells acquire somatic mutations that lead to uncontrolled gastrin secretion.

Genetic risk factors

• Multiple endocrine neoplasia type 1 (MEN‑1) – a hereditary syndrome caused by mutations in the MEN1 tumor suppressor gene. About 20‑30 % of ZES patients have MEN‑1.
• Familial isolated gastrinoma – rare families with autosomal dominant inheritance but without other MEN‑1 features.

Other risk factors

• Age > 30 years (most cases diagnosed in adulthood).
• Male or female sex – no clear predominance.
• Previous exposure to ionizing radiation (the data are limited but have been suggested in some case series).

Diagnosis

Because symptoms overlap with common peptic ulcer disease, a high index of suspicion is essential, especially when ulcers are refractory, multiple, or located distal to the duodenum.

Biochemical testing

• Fasting serum gastrin level – a level > 1000 pg/mL (or > 10× upper limit) in the presence of gastric acidity is highly suggestive. Values between 100–1000 pg/mL require a secretin stimulation test.
• Secretin stimulation test – paradoxical rise in gastrin (> 120 pg/mL) after IV secretin administration is diagnostic.
• pH measurement – gastric pH < 2 confirms hyperacidity.

Imaging studies

• Endoscopic ultrasound (EUS) – high‑resolution imaging for small pancreatic or duodenal lesions.
• Multiphasic contrast‑enhanced CT or MRI – assesses size, local invasion, and metastases (especially liver involvement).
• Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – highly sensitive for NET detection and staging.
• Selective arterial secretagogue injection (SASI) test – rarely used; localizes gastrin secretion by measuring hepatic venous gastrin after selective arterial stimulation.

Pathology

If surgical resection is performed, the tumor is examined histologically. Immunohistochemistry shows positivity for gastrin, chromogranin A, and synaptophysin. Ki‑67 proliferative index helps grade the tumor (G1‑G3).

Treatment Options

Management requires controlling acid hypersecretion, removing or controlling tumor growth, and addressing metastatic disease when present.

Acid‑suppression therapy (first line)

• High‑dose proton‑pump inhibitors (PPIs) – e.g., omeprazole 60 mg daily or equivalent. Doses are titrated to maintain gastric pH > 4.
• Histamine‑2 receptor antagonists (H2 blockers) – can be added for breakthrough symptoms, but PPIs are superior.

Surgical management

• Curative resection – Enucleation or pancreatoduodenectomy for localized gastrinomas. Offers the best chance for long‑term remission.
• Lymph node dissection – recommended because regional nodes are commonly involved.
• Metastasectomy – removal of isolated liver metastases improves survival in selected patients.

Medical therapies for unresectable or metastatic disease

• Somatostatin analogs (octreotide, lanreotide) – inhibit gastrin release and may stabilize tumor growth.
• Targeted therapy – Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) have FDA approval for progressive, well‑differentiated pancreatic NETs.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; improves progression‑free survival.
• Chemotherapy – Typically reserved for high‑grade (G3) neuroendocrine carcinomas (e.g., streptozocin + 5‑FU or temozolomide‑based regimens).

Liver‑directed therapies (if hepatic metastases)

• Radiofrequency ablation, trans‑arterial embolization, or Y‑90 radioembolization.

Lifestyle and supportive measures

• Avoid NSAIDs, aspirin, and alcohol, which aggravate ulcer disease.
• Small, frequent meals reduce gastric acid load.
• Supplement fat‑soluble vitamins (A, D, E, K) and calcium if malabsorption occurs.
• Vaccinate against hepatitis B if receiving systemic chemotherapy or PRRT.

Living with Zollinger‑Ellison Associated Gastrin‑Producing Neuroendocrine Tumor

Daily management tips

• Medication adherence – Take PPIs exactly as prescribed; missing doses can cause severe rebound acid hypersecretion.
• Regular follow‑up labs – Check fasting gastrin, liver function tests, and chromogranin A every 3‑6 months.
• Imaging surveillance – Annual MRI or CT to monitor for tumor recurrence or new metastases.
• Nutrition – Work with a dietitian to ensure adequate protein and calories; consider medium‑chain triglyceride (MCT) oils that are less dependent on pancreatic enzymes.
• Stress management – Chronic illness can increase anxiety; mindfulness, yoga, or counseling can improve quality of life.
• Support groups – Organizations such as the Neuroendocrine Tumor Research Foundation (NETRF) provide peer support and updated research information.

Medication safety

Long‑term high‑dose PPI use has been associated with increased risk of:

• Magnesium deficiency – monitor serum Mg every 6‑12 months.
• Vitamin B12 deficiency – check levels annually.
• Clostridioides difficile infection – report persistent diarrhea.

Prevention

Because most gastrinomas arise sporadically, primary prevention is limited. However, risk can be reduced in the following ways:

• Genetic counseling for families with MEN‑1 or known familial gastrinoma; early screening with fasting gastrin and imaging can detect tumors before complications develop.
• Avoid chronic gastric irritants – limit NSAID use and excessive alcohol.
• Early treatment of peptic ulcer disease – prompt eradication of Helicobacter pylori reduces ulcer burden, although it does not prevent gastrinoma formation.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated peptic ulcer – emergency surgery is required; mortality up to 15 % in older adults.
• Gastrointestinal bleeding – may present as melena or hematemesis.
• Severe malnutrition – chronic diarrhea and acid‑inactivated pancreatic enzymes cause weight loss and vitamin deficiencies.
• Metastatic disease – liver is the most common site; metastases reduce long‑term survival (5‑year survival ~60 % for localized disease vs. ~30 % with liver metastases).
• Electrolyte disturbances – chronic diarrhea can cause hypokalemia and metabolic alkalosis.
• Secondary infections – high‑dose PPI therapy increases risk of C. difficile colitis.

When to Seek Emergency Care

References

• Mayo Clinic. Zollinger‑Ellison syndrome. Updated 2023.
• National Institutes of Health (NIH). Neuroendocrine Tumors: Epidemiology and Management. 2022.
• American College of Gastroenterology. Guidelines for Diagnosis and Management of Gastric Acid–Related Disorders. 2021.
• Cleveland Clinic. Zollinger‑Ellison Syndrome. 2024.
• World Health Organization. Classification of Tumors of the Digestive System, 5th Edition. 2020.
• Strosberg JR, et al. Phase 3 Trial of ^177Lu‑DOTATATE for Midgut Neuroendocrine Tumors. New England Journal of Medicine. 2017;376:125–135.

```